# Patient-Trial Match Report

*Generated: 2026-01-05 06:55:49*

## Patient Profile

- **Age**: 52
- **Sex**: Female
- **Cancer Type**: NSCLC
- **Biomarkers**: EGFR exon 19 deletion

**Clinical Description**:
> 52-year-old Asian female with EGFR-mutant (exon 19 deletion) metastatic NSCLC. Initially treated with osimertinib with excellent response lasting 18 months. Now progressed with new bone metastases and enlarging lung primary. Liquid biopsy shows acquired C797S resistance mutation. No CNS involvement. Interested in combination trials or next-generation EGFR inhibitors. Never smoker, excellent functional status. No significant comorbidities. Labs: all WNL including LFTs.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 10
- **Total trials evaluated**: 88
- **Excluded by fast filter**: 28
- **LLM scored**: 60

## üü¢ HIGH Likelihood (10 trials)

### [NCT04486833](https://clinicaltrials.gov/study/NCT04486833)

**A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer**

- **Sponsor**: Genprex, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has NSCLC (non-small cell lung cancer) which matches the trial conditions.
- Patient is 52 years old, above the minimum age of 18.
- Patient has EGFR mutation positive (exon 19 deletion).
- Patient has acceptable ECOG status (0).
- Patient has documented progression on osimertinib and has measurable disease.

**? Uncertainties:**
- Labs for organ function (ANC, platelets, creatinine, bilirubin, AST, ALT, LVEF) are within normal limits but are not explicitly stated.
- Duration since last treatment with osimertinib is not provided.

**Assessment:**
> The patient's disease type matches the trial (NSCLC) and she has previously been treated with osimertinib, which is a required prior therapy. She meets key eligibility criteria such as age, ECOG status, and mutation type, with minor uncertainties related to organ function labs and treatment duration.

---

### [NCT05261399](https://clinicaltrials.gov/study/NCT05261399)

**A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).**

- **Sponsor**: AstraZeneca
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has histologically confirmed metastatic NSCLC.
- Patient has documented sensitising EGFR mutation (exon 19 deletion).
- Patient has documented radiologic progression on treatment with osimertinib.
- Patient has ECOG performance status of 0.
- Patient's labs are all within normal limits including LFTs.

**? Uncertainties:**
- Need to verify if MET overexpression/amplification has been documented in the patient's tumor specimen following progression.

**Assessment:**
> The patient's metastatic NSCLC diagnosis matches the trial criteria, and she has the required EGFR mutation and progression on osimertinib. Her ECOG status is acceptable, and her overall health appears good based on lab results. The only uncertainty is regarding the documentation of MET overexpression/amplification.

---

### [NCT06706076](https://clinicaltrials.gov/study/NCT06706076)

**A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)**

- **Sponsor**: BlossomHill Therapeutics
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 52
- Sex: female
- Cancer type: NSCLC
- Biomarkers: EGFR exon 19 deletion
- ECOG status: 0
- Prior therapies: osimertinib
- No brain metastases
- Country: United States

**? Uncertainties:**
- Measurable target extracranial lesion according to RECIST v1.1
- Adequate hematologic, hepatic, and renal function is not explicitly confirmed

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's focus on advanced NSCLC with EGFR mutations. The patient has received prior treatment, which aligns with the trial's inclusion of previously treated patients. However, there are uncertainties regarding the presence of measurable lesions and confirmation of organ function labs.

---

### [NCT07155187](https://clinicaltrials.gov/study/NCT07155187)

**Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI**

- **Sponsor**: AbbVie
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed diagnosis of metastatic non-squamous non-small cell lung cancer (NSCLC)
- Patient has documented EGFR exon 19 deletion
- ECOG Performance Status is 0
- Patient received osimertinib as the prior third-generation EGFR TKI and experienced disease progression

**? Uncertainties:**
- Archived or recently obtained tumor tissue during Screening (not mentioned) 
- At least 1 measurable lesion per RECIST version 1.1 (not specified in the patient's profile)

**Assessment:**
> The patient's cancer type (NSCLC) and specific EGFR mutation (exon 19 deletion) align with the trial's investigation. The patient has previously received a third-generation EGFR TKI and has an ECOG status of 0, making the patient likely eligible for the study with only minor uncertainties regarding additional tumor tissue and measurable lesions.

---

### [NCT04762199](https://clinicaltrials.gov/study/NCT04762199)

**A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer**

- **Sponsor**: Emory University
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Histologically confirmed metastatic non-small cell lung cancer (NSCLC)
- ECOG performance status of 0
- PD-L1 TPS of 5%
- Has acquired C797S resistance mutation
- No brain metastases

**? Uncertainties:**
- No specific information on lab values (e.g., absolute neutrophil count, platelet count, hemoglobin, bilirubin, serum creatinine, ALT, AST)

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's indication, and the patient has prior treatment with osimertinib, making her eligible for the Dose Expansion Cohort B as a previously treated patient with progression on osimertinib. The ECOG status and absence of brain metastases further support eligibility, though some lab values are unknown.

---

### [NCT06659458](https://clinicaltrials.gov/study/NCT06659458)

**Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients**

- **Sponsor**: Our Lady of the Lake Hospital
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age: 52
- Biologically born female
- Diagnosed with EGFR positive lung cancer (NSCLC with EGFR exon 19 deletion)

**? Uncertainties:**
- None

**Assessment:**
> The patient's cancer type matches the trial's conditions as she has EGFR positive NSCLC. She is within the age range and biologically female, qualifying her for the cancer group. There are no conflicts or uncertainties affecting eligibility.

---

### [NCT00068003](https://clinicaltrials.gov/study/NCT00068003)

**Cell Harvest and Preparation for Surgery Branch Treatment Protocols**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Enrolling by invitation
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Patient has NSCLC (Non-Small Cell Lung Cancer) which is one of the cancer types studied in the trial.
- Patient is 52 years old, which meets the age criteria (greater than or equal to 18 years).
- Patient's ECOG status is 0, meeting the performance status criteria.

**? Uncertainties:**
- Serology status for HIV, hepatitis B, and hepatitis C is not provided.
- Presence of accessible lesions for harvesting is not mentioned.

**Assessment:**
> The patient's cancer type matches the trial's focus on NSCLC, and they meet the age and performance status criteria. There are some uncertainties regarding serology and tumor accessibility, but overall eligibility is likely.

---

### [NCT06896162](https://clinicaltrials.gov/study/NCT06896162)

**PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival**

- **Sponsor**: UNC Lineberger Comprehensive Cancer Center
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**‚úì Supporting Factors:**
- Age ‚â• 18 years at the time of consent
- ECOG status of 0
- Documented Stage IV solid tumor malignancy: NSCLC
- Patient has undergone prior systemic therapy with osimertinib, which is acceptable for this study as it is not specified to be first-line only
- Next Generation Sequencing (NGS) testing is deemed appropriate by treating provider and results will be considered in therapy

**? Uncertainties:**
- A genomic tumor test has not been ordered or has been ordered but not resulted

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial indication, and she meets the age and ECOG criteria. She has received prior therapy, which is acceptable as the trial does not explicitly state first-line only. However, there remains some uncertainty about the status of genomic testing.

---

### [NCT05005403](https://clinicaltrials.gov/study/NCT05005403)

**A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab**

- **Sponsor**: AbbVie
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**‚úì Supporting Factors:**
- NSCLC cancer type matches the trial conditions
- ECOG status of 0 is acceptable
- Prior therapy with osimertinib aligns with eligibility for advanced NSCLC with actionable gene alterations
- No brain metastases present

**? Uncertainties:**
- Pre Treatment biopsy or archive tissue status within 6 months
- Laboratory values meeting protocol criteria
- Measurable disease status per RECIST

**Assessment:**
> The patient's NSCLC diagnosis aligns with the trial's focus on non-small cell lung cancer. The patient's treatment history indicates they have progressed after osimertinib, which meets the required prior treatment conditions. The ECOG status is acceptable, and there are no brain metastases. However, the uncertainty regarding recent biopsy availability and lab values available may need further verification.

---

### [NCT06545331](https://clinicaltrials.gov/study/NCT06545331)

**A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors**

- **Sponsor**: Exelixis
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**‚úì Supporting Factors:**
- Patient has metastatic NSCLC, which matches the trial's conditions studied.
- Patient is 52 years old, which meets the minimum age requirement of 18.
- Patient has ECOG status 0, which is acceptable for the trial.
- Patient has adequate organ function, as indicated by labs being WNL.

**‚úó Potential Conflicts:**
- Patient has prior systemic therapy (osimertinib), but the trial does not specify if it is only for treatment-naive patients, making it unclear if this would exclude them.

**? Uncertainties:**
- The trial eligibility criteria do not specify if it is open to previously treated patients or only for treatment-naive patients.

**Assessment:**
> The patient has a cancer type that aligns with the trial's conditions studied and meets critical criteria such as age and ECOG status. However, there is uncertainty regarding the allowance for previously treated patients, as the trial does not explicitly define this.

---

## üü° MEDIUM Likelihood (3 trials)

### [NCT05498428](https://clinicaltrials.gov/study/NCT05498428)

**A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**‚úì Supporting Factors:**
- Patient has histologically confirmed metastatic non-small cell lung cancer (NSCLC)
- Patient has an EGFR exon 19 deletion mutation
- Patient has ECOG status of 0

**‚úó Potential Conflicts:**
- Patient has received prior systemic therapy (osimertinib) which is a requirement for Cohorts 3 and 3b but not for Cohorts 1, 2, 5, 6, and 7
- Patient shows acquired resistance mutation (C797S) which may impact eligibility depending on specific cohort requirements

**? Uncertainties:**
- Specific cohort eligibility (Patient could qualify for Cohort 3 or 3b but needs confirmation about progression after osimertinib)

**Assessment:**
> The patient's cancer type is appropriate as they have metastatic NSCLC that matches the trial. They also have the required biomarker mutation (EGFR exon 19 deletion) and an ECOG status of 0, but their prior treatment with osimertinib raises concerns about the treatment line eligibility, particularly for Cohorts 1, 2, 5, 6, and 7, while they may qualify for Cohorts 3 and 3b. The presence of acquired resistance mutation complicates the assessment further.

---

### [NCT02178163](https://clinicaltrials.gov/study/NCT02178163)

**A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.**

- **Sponsor**: Barbara Ann Karmanos Cancer Institute
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 65%

**‚úì Supporting Factors:**
- Stage IV Non-Small Cell Lung Cancer
- ECOG status 0

**‚úó Potential Conflicts:**
- Patient has prior systemic therapy (osimertinib) but trial does not specify if previously treated patients are allowed.

**? Uncertainties:**
- Specific laboratory test results within 30 days are not provided.
- Biopsy requirements related to prior treatments and timing are unclear.

**Assessment:**
> The disease type matches as the patient has NSCLC and is in a Stage IV context, which aligns with the trial's focus on advanced NSCLC. However, the patient has a history of prior therapy (osimertinib), and it is unclear if previously treated patients are accepted in this trial, which introduces uncertainty in eligibility. More information on lab tests and biopsy criteria is needed.

---

### [NCT06400472](https://clinicaltrials.gov/study/NCT06400472)

**A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor Œ±-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 55%

**‚úì Supporting Factors:**
- Cancer type is NSCLC, which is included in trial conditions
- ECOG status is 0, which is acceptable for the trial
- No brain metastases, meeting one of the standard eligibility criteria

**‚úó Potential Conflicts:**
- Patient has prior systemic therapy (osimertinib), but trial may require treatment-naive status
- Patient's PD-L1 TPS is 5%, which does not meet any specified biomarker thresholds for eligibility

**? Uncertainties:**
- No details on treatment line or whether prior therapy disqualifies
- No explicit requirements for the specific biomarker or treatment history mentioned in trial details

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's target indication. However, the patient has prior therapy (osimertinib), creating uncertainty regarding the treatment line eligibility. Additionally, the patient's PD-L1 TPS at 5% does not appear to meet any threshold, further complicating eligibility assessment. The overall assessment reflects these uncertainties.

---

## Excluded (75 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04083183](https://clinicaltrials.gov/study/NCT04083183) | Patient age 52 is above maximum age 49 |
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04300556](https://clinicaltrials.gov/study/NCT04300556) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04316546](https://clinicaltrials.gov/study/NCT04316546) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05419375](https://clinicaltrials.gov/study/NCT05419375) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05702034](https://clinicaltrials.gov/study/NCT05702034) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05785741](https://clinicaltrials.gov/study/NCT05785741) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05892068](https://clinicaltrials.gov/study/NCT05892068) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05925803](https://clinicaltrials.gov/study/NCT05925803) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Patient age 52 is above maximum age 30 |
| [NCT06973564](https://clinicaltrials.gov/study/NCT06973564) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07125183](https://clinicaltrials.gov/study/NCT07125183) | Patient age 52 is below minimum age 65 |
| [NCT00033137](https://clinicaltrials.gov/study/NCT00033137) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT01970696](https://clinicaltrials.gov/study/NCT01970696) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03465774](https://clinicaltrials.gov/study/NCT03465774) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04458532](https://clinicaltrials.gov/study/NCT04458532) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04551378](https://clinicaltrials.gov/study/NCT04551378) | Patient age 52 is above maximum age 39 |
| [NCT04815356](https://clinicaltrials.gov/study/NCT04815356) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04985032](https://clinicaltrials.gov/study/NCT04985032) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05598879](https://clinicaltrials.gov/study/NCT05598879) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 8 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT03948100](https://clinicaltrials.gov/study/NCT03948100) | M.D. Anderson Cancer | Patient has prior therapy with osimertinib, which indicates they are not treatment-naive and the trial may require untreated patients. |
| [NCT03586453](https://clinicaltrials.gov/study/NCT03586453) | Dana-Farber Cancer I | Patient has received prior treatment with osimertinib, but the trial is for EGFR inhibitor-na√Øve advanced NSCLC. |
| [NCT04155034](https://clinicaltrials.gov/study/NCT04155034) | SWOG Cancer Research | Patient has non-small cell lung cancer (NSCLC) while the trial targets small cell lung cancer (SCLC). |
| [NCT04181060](https://clinicaltrials.gov/study/NCT04181060) | National Cancer Inst | Patient has prior treatment with osimertinib, but the trial requires patients that have not received any treatment with an anti-VEGF agent and specifies prior treatment with an EGFR TKI is not allowed. |
| [NCT04317534](https://clinicaltrials.gov/study/NCT04317534) | Greg Durm, MD | Patient has stage IV NSCLC due to new bone metastases, which makes her ineligible for the trial targeting Stage I NSCLC. |
| [NCT05578326](https://clinicaltrials.gov/study/NCT05578326) | UNC Lineberger Compr | Patient has NSCLC but the trial is for Small Cell Lung Cancer (SCLC) |
| [NCT05642572](https://clinicaltrials.gov/study/NCT05642572) | SWOG Cancer Research | Patient has EGFR C797S mutation, indicating acquired resistance, which may not meet the trial's requirement for a MET amplification as required by the eligibility criteria. |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Bristol-Myers Squibb | Patient has prior treatment with osimertinib but the trial only accepts treatment-naive patients. |
| [NCT06593522](https://clinicaltrials.gov/study/NCT06593522) | Amgen | Patient has EGFR mutation (C797S) which is excluded by the trial criteria. The trial excludes tumors harboring mutations amenable to targeted therapies such as EGFR. |
| [NCT03774758](https://clinicaltrials.gov/study/NCT03774758) | University of Califo | Patient has prior treatment with osimertinib, but the trial does not specify eligibility for previously treated patients. |
| [NCT04577599](https://clinicaltrials.gov/study/NCT04577599) | Wake Forest Universi | Patient has a known diagnosis of lung cancer (NSCLC) in the past 5 years which excludes them from the trial. |
| [NCT05332925](https://clinicaltrials.gov/study/NCT05332925) | Jun Zhang, MD, PhD | Patient has prior therapy with osimertinib and trial requires treatment-naive patients. |
| [NCT06124508](https://clinicaltrials.gov/study/NCT06124508) | University of Miami | Patient has a diagnosis of lung cancer (NSCLC) which is an active malignancy, while the trial excludes individuals with any active malignancy. |
| [NCT06124118](https://clinicaltrials.gov/study/NCT06124118) | University of Utah | Patient has received prior systemic therapy (osimertinib) while the trial is for treatment-naive patients. |
| [NCT06712745](https://clinicaltrials.gov/study/NCT06712745) | University of Texas  | Patient has prior therapy with osimertinib, while the trial does not specify that it accepts previously treated patients. |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Mayo Clinic | Patient has undergone prior systemic therapy (osimertinib), which is not compatible with the eligibility for treatment-naive patients. |
| [NCT07132918](https://clinicaltrials.gov/study/NCT07132918) | University of Wiscon | Patient has metastatic NSCLC and the trial only includes non-operable Stage III NSCLC. |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | University of Arizon | Patient has NSCLC while the trial primarily studies tumors expressing DLL3, with no mention of NSCLC as a required type based on incomplete histologies. |
| [NCT06426628](https://clinicaltrials.gov/study/NCT06426628) | Veracyte, Inc. | Patient has active cancer (NSCLC) but trial excludes active cancer (other than non-melanoma skin cancer). |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Merck Sharp & Dohme  | Patient has prior systemic therapy (osimertinib) but the trial is designed for patients who have not received prior therapies |
| ... | ... | *and 27 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| EGFR exon 19 deletion | manual | 1.0 |
| NSCLC | manual | 1.0 |
| EGFR exon 19 deletion NSCLC | manual | 1.0 |
| EGFR exon 19 deletion non-small cell lung cancer | llm | 0.9 |
| EGFR exon 19 deletion metastatic NSCLC | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung cancer | llm | 0.8 |
| EGFR p.L858R | llm | 0.9 |
| EGFRp.L858R | llm | 0.8 |
| EGFR-p.L858R | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
